New Risk • Mar 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (₪306k revenue, or US$97k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (169% net profit margin). New Risk • Mar 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Revenue is less than US$1m (₪306k revenue, or US$100k). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (169% net profit margin). Buy Or Sell Opportunity • Feb 25
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to ₪1.04. The fair value is estimated to be ₪1.31, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.3% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Jan 12
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 8.3% to ₪1.00. The fair value is estimated to be ₪1.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.3% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Jan 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₪306k revenue, or US$96k). Minor Risks Share price has been volatile over the past 3 months (5.7% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (169% net profit margin). Market cap is less than US$100m (₪130.6m market cap, or US$41.0m). Duyuru • Dec 17
Dna Group (T.R.) Ltd, Annual General Meeting, Dec 30, 2025 Dna Group (T.R.) Ltd, Annual General Meeting, Dec 30, 2025. Location: co. offices, Israel Duyuru • Nov 12
Dna Group (T.R.) Ltd announced that it expects to receive funding from Israel Canada (T.R) Ltd Dna Group (T.R.) Ltd announced private placement of 543,476,453 common shares on November 10, 2025. The transaction includes participation fromIsrael Canada (T.R) Ltd for 462,360,424 shares and Reuven Alex for 81,116,029 shares. Buy Or Sell Opportunity • Sep 15
Now 21% undervalued Over the last 90 days, the stock has risen 4.9% to ₪1.01. The fair value is estimated to be ₪1.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.3% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Aug 31
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 169% Last year net profit margin: 4,919% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₪306k revenue, or US$92k). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (169% net profit margin). Market cap is less than US$100m (₪124.0m market cap, or US$37.2m). Buy Or Sell Opportunity • Jun 03
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 14% to ₪0.96. The fair value is estimated to be ₪1.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • May 05
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.4% to ₪1.00. The fair value is estimated to be ₪1.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Apr 15
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₪1.03, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 12x in the Electronic industry in Israel. Total loss to shareholders of 40% over the past three years. Buy Or Sell Opportunity • Apr 01
Now 20% undervalued Over the last 90 days, the stock has risen 6.0% to ₪0.96. The fair value is estimated to be ₪1.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Mar 16
Full year 2024 earnings released: EPS: ₪0.18 (vs ₪0.01 loss in FY 2023) Full year 2024 results: EPS: ₪0.18 (up from ₪0.01 loss in FY 2023). Net income: ₪23.4m (up ₪24.6m from FY 2023). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. New Risk • Mar 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). High level of non-cash earnings (63% accrual ratio). Revenue is less than US$1m (₪306k revenue, or US$84k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (₪123.9m market cap, or US$33.9m). Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₪1.05, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 15x in the Electronic industry in Israel. Total loss to shareholders of 27% over the past three years. Valuation Update With 7 Day Price Move • Dec 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₪1.10, the stock trades at a trailing P/E ratio of 9x. Average trailing P/E is 14x in the Electronic industry in Israel. Total loss to shareholders of 23% over the past three years. Duyuru • Nov 11
Dna Group (T.R.) Ltd, Annual General Meeting, Nov 25, 2024 Dna Group (T.R.) Ltd, Annual General Meeting, Nov 25, 2024. Location: co. offices, Israel New Risk • Apr 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₪306k revenue, or US$82k). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (₪124.0m market cap, or US$33.1m). Board Change • Aug 05
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent External Director Ronen Midbari was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jul 19
Investor sentiment improved over the past week After last week's 16% share price gain to ₪1.37, the stock trades at a trailing P/E ratio of 8.9x. Average trailing P/E is 17x in the Electronic industry in Israel. Total returns to shareholders of 1.7% over the past three years. Valuation Update With 7 Day Price Move • May 31
Investor sentiment improved over the past week After last week's 15% share price gain to ₪1.39, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 16x in the Electronic industry in Israel. Negligible returns to shareholders over past three years. Valuation Update With 7 Day Price Move • Oct 27
Investor sentiment improved over the past week After last week's 24% share price gain to ₪1.50, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 23x in the Electronic industry in Israel. Negligible returns to shareholders over past three years. Is New 90 Day High Low • Mar 11
New 90-day high: ₪1.40 The company is up 88% from its price of ₪0.75 on 10 December 2020. The Israeli market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electronic industry, which is up 9.0% over the same period. Is New 90 Day High Low • Feb 03
New 90-day high: ₪1.11 The company is up 49% from its price of ₪0.74 on 04 November 2020. The Israeli market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electronic industry, which is up 14% over the same period. Is New 90 Day High Low • Jan 04
New 90-day high: ₪0.97 The company is up 39% from its price of ₪0.70 on 06 October 2020. The Israeli market is up 22% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electronic industry, which is up 16% over the same period. 